Veeva Systems Inc. — Form 10-Q Summary
Business and period: Veeva provides cloud software and data solutions primarily to life sciences companies. This report covers the quarter and six months ended July 31, 2016 (fiscal Q2 and first half of FY2017); comparisons are with the corresponding 2015 periods. Amounts below are in U.S. dollars.
Financial performance and liquidity
- Q2 revenue: $131.3 million, up 34% year over year. Subscription revenue was $105.2 million (+40%); professional services and other revenue was $26.1 million (+14%). Subscription services rose to 80% of revenue from 77%.
- Q2 profitability: Gross profit was $89.2 million, with a 67.9% gross margin versus 65.9%. Operating income was $23.8 million versus $22.4 million, but operating margin declined to 18.1% from 22.9%. Net income was $13.0 million, down from $13.4 million; diluted EPS was $0.09, unchanged.
- First-half results: Revenue was $251.1 million (+34%); subscription revenue was $201.2 million (+40%). Gross margin improved to 66.8% from 65.2%. Operating income declined to $41.6 million from $43.3 million, and net income to $25.5 million from $26.4 million. Diluted EPS was $0.17 versus $0.18.
- Expenses and margins: First-half operating expenses rose 59% to $126.2 million, led by higher research and development and sales and marketing spending. Stock-based compensation was $10.0 million in Q2 and $18.2 million in the first half.
- Cash flow: Operating cash flow was $11.7 million in Q2 versus $15.2 million; for the first half it was $121.1 million versus $57.0 million. First-half cash generation benefited from a $56.0 million reduction in accounts receivable and a $19.3 million increase in deferred revenue. Management said much of the expected fiscal-year operating cash flow occurred in the first half and expects quarterly operating cash flow to be minimal for the rest of the year.
- Liquidity and debt: Cash, cash equivalents and short-term investments totaled $479.6 million at July 31, 2016; total current assets were $587.1 million and current liabilities $208.1 million. The filing reports no borrowings in the presented balance sheet. Deferred revenue was $176.7 million.
Changes, outlook and material items
- Revenue growth was driven chiefly by new orders: management attributed 96% of Q2 subscription revenue growth to orders placed after July 31, 2015, including Zinc Ahead, acquired in September 2015. Existing-customer renewals and expansion accounted for the remainder. First-half proportions were 83% new orders and 17% existing-customer orders/renewals.
- Management expects continued investment in product development, sales, marketing, professional services and international expansion. It anticipates expenses rising and says operating margin may decrease slightly; it also expects revenue growth rates may decline over time. No quantified forward revenue or earnings guidance is stated in the supplied filing text.
- Salesforce.com agreement commitments were $397.5 million of future minimum payments, including $382.3 million still obligated as of July 31, through September 2025. The agreement includes a $500 million minimum order commitment and potential true-up payments.
- A May 2016 Salesforce service outage affected 38 Veeva CRM customers for up to 21 hours. Some customers may have up to four hours of transactional data not restored; claimed service credits were immaterial as of quarter-end, and management did not expect a material future impact.
- Q2 other expense included a $1.1 million foreign-currency loss; management identifies the U.S. dollar, euro, pound and yen as currency exposures. A 100-basis-point rate increase was estimated to reduce investment portfolio fair value by $2.1 million.
- The effective tax rate increased to 42.3% in Q2 and 40.8% for the first half, primarily due to a valuation allowance against certain Mederi AG deferred tax assets, partly offset by the U.S. R&D tax credit.
- The company reported that a previously disclosed material weakness concerning review of acquired intangible-asset valuation inputs was remediated as of July 31, 2016. It reported disclosure controls effective at a reasonable assurance level.
- Risks highlighted include reliance on life sciences and Veeva CRM, competition and adoption of newer products, customer renewals and concentration, security and service availability, third-party hosting and Salesforce dependence, regulatory/privacy changes including Brexit-related uncertainty, and execution of Zinc Ahead integration. The company stated it knew of no legal proceeding expected to have a material adverse effect; a stockholder Section 16(b) case against third parties remained pending.
Investor verification points
- Assess whether subscription growth and customer expansion can offset dependence on new orders and potential deceleration in overall growth.
- Track operating margin, expense growth, and the effect of stock-based compensation and acquisition-related amortization.
- Evaluate the sustainability of operating cash flow, given first-half working-capital benefits and management’s expectation of minimal cash flow in later quarters.
- Review Salesforce minimum commitments, hosting dependence, outage remediation and data-restoration implications.
- Monitor Zinc Ahead customer migration and integration, tax-asset valuation assumptions, foreign-exchange exposure, and the effectiveness of the remediated control procedures.